Literature DB >> 23321357

Visual performance and the ocular surface in traumatic brain injury.

Glenn C Cockerham1, Sonne Lemke, Catherine Glynn-Milley, Lars Zumhagen, Kimberly P Cockerham.   

Abstract

The pathophysiology of neurotrauma is reviewed and an original study investigating the prevalence of dry eye disease in a sample of veterans with traumatic brain injury (TBI) is presented. Fifty-three veterans with TBI were evaluated by history of injury, past ocular history, and medication use. Ocular Disease Surface Index (OSDI), ocular examination, cranial nerve evaluation, tear osmolarity, tear film break-up time (TFBUT), ocular surface staining and tear production testing were performed. A matched comparison group underwent similar testing. TBI causes were blast (44) or non-blast (9). TBI subjects scored significantly worse on the OSDI (P<.001), and ocular surface staining by Oxford scale (P<.001) than non-TBI subjects. Scores for tear film breakup (P=.6), basal tear production less than 3 mm (P=.13), and tear osmolarity greater than 314 mOsm/L (P=.15) were all higher in TBI subjects; significantly more TBI subjects had at least one abnormal dry eye measure than comparisons (P<.001). The OSDI related to presence of dry eye symptoms (P<.01). These effects were present in both blast and non-blast TBI. Seventy percent of TBI subjects were taking at least one medication in the following classes: antidepressant, atypical antipsychotic, anticonvulsant, or h1-antihistamine. There was no association between any medication class and the OSDI or dry eye measures. Reduced corneal sensation in 21 TBI subjects was not associated with OSDI, tear production, or TFBUT, but did correlate with reduced tear osmolarity (P=.05). History of refractive surgery, previous contact lens wear, facial nerve weakness, or meibomian gland dysfunction was not associated with DED. In summary, we found a higher prevalence of DED in subjects with TBI, both subjectively and objectively. This effect is unrelated to medication use, and it may persist for months to years. We recommend that patients with TBI from any cause be evaluated for DED using a battery of standard testing methods described in a protocol presented in this article. Further research into the pathophysiology and outcomes of DED in neurotrauma is needed. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2012        PMID: 23321357     DOI: 10.1016/j.jtos.2012.09.004

Source DB:  PubMed          Journal:  Ocul Surf        ISSN: 1542-0124            Impact factor:   5.033


  5 in total

1.  Amelioration of visual deficits and visual system pathology after mild TBI with the cannabinoid type-2 receptor inverse agonist SMM-189.

Authors:  Natalie M Guley; Nobel A Del Mar; Tyler Ragsdale; Chunyan Li; Aaron M Perry; Bob M Moore; Marcia G Honig; Anton Reiner
Journal:  Exp Eye Res       Date:  2019-03-26       Impact factor: 3.467

2.  Neurodegeneration and Vision Loss after Mild Blunt Trauma in the C57Bl/6 and DBA/2J Mouse.

Authors:  Courtney Bricker-Anthony; Tonia S Rex
Journal:  PLoS One       Date:  2015-07-06       Impact factor: 3.240

3.  Exacerbation of blast-induced ocular trauma by an immune response.

Authors:  Courtney Bricker-Anthony; Jessica Hines-Beard; Lauren D'Surney; Tonia S Rex
Journal:  J Neuroinflammation       Date:  2014-11-29       Impact factor: 8.322

Review 4.  Tear film osmolarity and dry eye disease: a review of the literature.

Authors:  Richard Potvin; Sarah Makari; Christopher J Rapuano
Journal:  Clin Ophthalmol       Date:  2015-11-02

5.  Identification of chronic brain protein changes and protein targets of serum auto-antibodies after blast-mediated traumatic brain injury.

Authors:  Matthew M Harper; Danielle Rudd; Kacie J Meyer; Anumantha G Kanthasamy; Vellareddy Anantharam; Andrew A Pieper; Edwin Vázquez-Rosa; Min-Kyoo Shin; Kalyani Chaubey; Yeojung Koh; Lucy P Evans; Alexander G Bassuk; Michael G Anderson; Laura Dutca; Indira T Kudva; Manohar John
Journal:  Heliyon       Date:  2020-02-17
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.